A Clinical Study to Evaluate CAD-1883 in Essential Tremor

Status Completed

Clinical Trial Summary

This is an open-label study designed to evaluate the safety, tolerability and efficacy of CAD-1883, a positive allosteric modulator of the SK channel, administered twice daily orally to adult patients with ET. Patients with the diagnosis of ET based on the Movement Disorder Society (MDS) criteria with a documented severity of tremor based on the clinician-administered TETRAS Performance Subscale are eligible to be enrolled in the study.

Clinical Trial Description

This is an open-label study designed to evaluate the safety, tolerability and efficacy of CAD-1883, a positive allosteric modulator (PAM) of the SK channel, administered twice daily orally to adult subjects with ET. Positive modulation of the small-conductance calcium-activated potassium channels (SK) present in different regions of the brain aims to increase the channel sensitivity to calcium resulting in reduction in neuronal firing rate. In patients with ET, improving the regularity of firing of action potentials in the olivo-cerebellar network can lead to improvement in motor function. During the Screening period, each subject will undergo full assessment including medical and treatment history for ET, physical examination and other screening assessments. Patients with the diagnosis of ET based on the Movement Disorder Society (MDS) criteria with a documented severity of tremor based on the clinician-administered TETRAS Performance Subscale are eligible to be enrolled in the study. The study consists of treatment groups receiving twice daily oral dosing of CAD-1883 for a treatment period of 14 days. This study is designed to enable the assessment of safety and tolerability of CAD-1883 in patients with ET as well as the determination of early treatment effect on reducing the magnitude and severity of tremor while limiting the potential risk associated with a novel investigational drug. Safety and tolerability will be monitored throughout the study duration including in-clinic assessments of adverse events (AEs), serious adverse events (SAEs), vital signs, 12-lead ECG, urinalysis, hematology, clinical chemistry, and CAD-1883 plasma concentration level on Days 1, 7, 14 and 21. Efficacy will be evaluated using the clinician-administered TETRAS Performance Subscale as well as the use of a wearable sensor in the clinic and at home. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03688685
Study type	Interventional
Source	Cadent Therapeutics
Contact
Status	Completed
Phase	Phase 2
Start date	January 23, 2019
Completion date	September 24, 2019

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT05381688` - VIM DBS Respiratory Modulation: N-of-1 Trial
Recruiting	`NCT05101161` - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes	N/A
Completed	`NCT02277106` - Evaluate SAGE-547 in Participants With Essential Tremor	Phase 2
Recruiting	`NCT05769933` - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Terminated	`NCT02678429` - Atlas Predicted DBS Settings in Essential Tremor	N/A
Terminated	`NCT02894567` - Evaluation of Directional Recording and Stimulation Using spiderSTN	N/A
Completed	`NCT02523807` - Tremor Monitoring Device	N/A
Active, not recruiting	`NCT02255929` - Gamma Knife Radiosurgery for Treatment of Essential Tremor	N/A
Completed	`NCT01223144` - Decision-making and Emotion Recognition in Essential Tremor	N/A
Completed	`NCT00906412` - Ventrointermediate Nucleus (VIM DBS) and Working Memory	N/A
Recruiting	`NCT05214222` - Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma	Phase 2
Completed	`NCT03051178` - Wearable Sensor for Responsive DBS for ET	N/A
Recruiting	`NCT03795935` - Relief From Side Effects: Clinical Use of Electrodes With Direction	N/A
Not yet recruiting	`NCT06036368` - Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor	N/A
Recruiting	`NCT05897775` - Coordinated Reset Deep Brain Stimulation for Essential Tremor	Phase 1
Recruiting	`NCT05968976` - Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET	N/A
Completed	`NCT06314139` - Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized Study.	N/A
Recruiting	`NCT04501133` - Sensory-specific Peripheral Stimulation for Tremor Management	N/A
Active, not recruiting	`NCT03560622` - Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy	N/A
Completed	`NCT00368199` - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.